IDH1 and central nervous system cancer: IDH1 was a key rate-limiting enzyme in the Krebs cycle (28, 29), and IDH1 mutation was a favorable independent prognostic factor for PFS in glioma (9, 10), and it also played an important role in the time of tumor recurrence and outcome of gliomas.